EUVIMEDEUVIMED entdecken
Open Access

Purine Metabolism Regulates the Severity of APOL1 Nephropathy

Huihui Huang iD, Calum Tattersfield iD, Sonako Jacas, Esilida S Karreci iD, Aarya Rumde iD, Jessica Kelly, Lauren Francey iD, Balajikarthick Subramanian iD, Ming Huang, Birgitta Ryback iD, Valerie Schumacher iD, Seth L Alper iD und 3 weitere

Journal of the American Society of Nephrology · 2026-11 · 37 (11) · 2421-2434

DOI: 10.1681/asn.0000001129 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Society of Nephrology, online erschienen am 08.05.2026. Verfasst von Huihui Huang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts. Hauptthemen laut MEDLINE: Apolipoprotein L1, Purines, Kidney Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIMHD NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Key Points Apolipoprotein L1 risk variants altered purine metabolic pathways. 5-aminoimidazole-4-carboxamide riboside supplementation alleviated apolipoprotein L1 risk variant–induced cytotoxicity.

Background

Thirteen percent of African American people have a high-risk apolipoprotein L1 ( APOL1) genotype, carrying two risk alleles (G1/G1, G1/G2, or G2/G2). The mechanisms underlying nephropathy caused by these APOL1 risk variant genotypes are not fully understood. Downstream of gene function, homeostatic maintenance of a complex and interconnected network of metabolites is essential for normal kidney function. However, this metabolic network can be rerouted by genetic changes or environmental insults, both of which can contribute to the development and/or progression of kidney diseases. APOL1 nephropathy exhibits both genetic and environmental triggers, but how APOL1 might alter metabolic homeostasis and how such changes may contribute to disease progression remains unclear.

Methods

APOL1 nephropathy was induced in human bacterial artificial chromosome transgenic APOL1 mice by IFN- γ adenovirus. Nontargeted metabolomics was performed on glomeruli from risk variant (G1/G1 and G2/G2) and nonrisk variant (G0/G0) mice as well as on tetracycline-inducible cell lines expressing risk or nonrisk variants. Metabolic signaling pathways in risk or nonrisk groups were compared, and transcriptional changes driving these metabolic differences were identified. Metabolic interventions were performed in both APOL1 risk and nonrisk variant–expressing cells and in mice. The effect of metabolic intervention was evaluated by cytotoxicity assays and urine albumin-to-creatinine ratios for cellular and in vivo responses, respectively.

Results

Perturbed purine metabolism was the strongest metabolite differentiator between high-risk and low-risk APOL1 genotypes in cultured cells and in whole glomeruli. Expression of APOL1 G2/G2 downregulated the rate-limiting enzymes of purine biosynthesis and induced ATP depletion. In APOL1 G2/G2-expressing cells, supplementation with the purine biosynthesis precursor 5-aminoimidazole-4-carboxamide riboside (AICAr) rescued purine biosynthesis, reduced cytotoxicity, and boosted ATP. In IFN- γ treated APOL1 G2/G2 transgenic mice, AICAr administration boosted purine biosynthesis, decreased kidney phosphorylated AMP-activated protein kinase, and reduced albuminuria levels. AICAr treatment rescued G2 mouse podocyte death induced by the inflammatory stimuli of combined IFN- γ and toll-like receptor 1/2 agonist.

Conclusions

Increasing purine biosynthesis mitigated APOL1 risk variant–induced injury in cell and transgenic mouse models of APOL1 kidney disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Apolipoprotein L1PurinesKidney DiseasesAnimalsHumansMiceMice, TransgenicAminoimidazole CarboxamideMale

Stichwörter der Autor:innen

apolipoprotein L1 (APOL1)basic sciencemechanismsmetabolism

Substanzen

Apolipoprotein L1APOL1 protein, humanPurinesAminoimidazole Carboxamide

Autor:innen und Institutionen

  • Division of Nephrology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.
  • Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Hamburg Center for Kidney Health (HCKH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Broad Institute of Harvard and MIT, Cambridge, Massachusetts.

ORCID-Profile: Huihui Huang, Calum Tattersfield, Esilida S Karreci, Aarya Rumde, Lauren Francey, Balajikarthick Subramanian, Birgitta Ryback, Valerie Schumacher, Seth L Alper, Zsuzsanna K Zsengellér, Martin R Pollak, David J Friedman

Förderung

  • NIDDK NIH HHS
  • NIMHD NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Huang, H., Tattersfield, C., Jacas, S., Karreci, E. S., Rumde, A., Kelly, J., Francey, L., Subramanian, B., Huang, M., Ryback, B., Schumacher, V., Alper, S. L., Zsengellér, Z. K., Pollak, M. R., & Friedman, D. J. (2026). Purine Metabolism Regulates the Severity of APOL1 Nephropathy. Journal of the American Society of Nephrology, 37(11), 2421-2434. https://doi.org/10.1681/asn.0000001129

Vancouver

Huang H, Tattersfield C, Jacas S, Karreci ES, Rumde A, Kelly J, et al. Purine Metabolism Regulates the Severity of APOL1 Nephropathy. Journal of the American Society of Nephrology. 2026;37(11):2421-2434. doi:10.1681/asn.0000001129

BibTeX
@article{Huang2026,
  author = {Huang, Huihui and Tattersfield, Calum and Jacas, Sonako and Karreci, Esilida S and Rumde, Aarya and Kelly, Jessica and Francey, Lauren and Subramanian, Balajikarthick and Huang, Ming and Ryback, Birgitta and Schumacher, Valerie and Alper, Seth L and Zsengellér, Zsuzsanna K and Pollak, Martin R and Friedman, David J},
  title = {Purine Metabolism Regulates the Severity of APOL1 Nephropathy},
  journal = {Journal of the American Society of Nephrology},
  year = {2026},
  volume = {37},
  number = {11},
  pages = {2421--2434},
  doi = {10.1681/asn.0000001129}
}
Kostenlos starten →